Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
The current status of three drugs of clinical interest to the National Cancer Institute is reviewed. m-AMSA, a drug with a wide spectrum of activity in murine tumors, is now in phase II trial and has shown itself to have a high order of activity in acute nonlymphocytic leukemia. Dihydroxyanthracenedione, a compound with some of the characteristics of anthracyclines but with no cardiac toxicity in animal toxicology studies, is in phase I evaluation. Deoxycoformycin, an adenosine analog which is a potent inhibitor of adenosine deaminase, has shown moderate activity in acute leukemia patients in phase I trials, and has the potential to produce synergistic antitumor toxicity when used with arabinofuranosyladenine.
D058892:Adenosine Deaminase Inhibitors; D000609:Aminoacridines / Q000627:therapeutic use*; D000677:Amsacrine; D000873:Anthracenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003070:Coformycin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008942:Mitoxantrone; D009369:Neoplasms / Q000188:drug therapy*; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D015649:Pentostatin; D012263:Ribonucleosides / Q000627:therapeutic use*
D058892:Adenosine Deaminase Inhibitors; D000609:Aminoacridines; D000873:Anthracenes; D000970:Antineoplastic Agents; D012263:Ribonucleosides; D000677:Amsacrine; D003070:Coformycin; D015649:Pentostatin; D008942:Mitoxantrone; D009700:Nucleoside Deaminases